A limitation of this study was that we were unable to analyze the expression of somatostatin receptor (especially SSTR2), ATRX, DAXX, and KRAS, as well as other markers, which are also considered useful for discriminating immunohistochemical and genetic findings between NET G3 and NEC. The gene discussed is ATRX; the disease is neuroendocrine carcinoma.